Zoetis Inc. reported second-quarter revenue of $2.5 billion, a 4% increase from a year earlier, while net income rose 15% to $718 million, or $1.61 per diluted share. Adjusted earnings reached $1.76 a share, helped by 8% organic operational revenue growth. The results sent the animal-health company’s stock up roughly 9% in pre-market trading. Growth was led by continued demand for companion-animal medicines such as Simparica Trio and dermatology treatments, which offset lower livestock sales following the divestiture of certain feed-additive products. In the United States, revenue climbed 4% to $1.4 billion, while international sales advanced 3% to $1.1 billion on a reported basis. On the strength of the first half, Zoetis raised its 2025 outlook. The company now expects full-year revenue of $9.45 billion to $9.60 billion, up from a prior range of $9.43 billion to $9.58 billion, and projects adjusted earnings of $6.30 to $6.40 a share, 10 cents higher at the midpoint than earlier guidance.